Type 2 Diabetes Mellitus
Conditions
Keywords
Metformin, Gastrointestinal side effects, Microbiota
Brief summary
Metformin has been used in Sweden since 1957, and it is recommended as first line therapy for type 2-diabetes (T2D) in national and international guidelines. However, adverse effects involving diarrhea, constipation, bloating, and abdominal pain are common which leads to discontinuation of medication or not being able to reach therapeutic doses. Here the investigators will perform a prospective study to investigate whether i) participants with T2D who experience adverse events following metformin treatment have an altered microbiota at baseline compared to participants without adverse events and ii) if the microbiota is altered in participants during onset of adverse events. The investigators hypothesis is that adverse effects associated with metformin are caused by an altered gut microbiota, either at base line or following metformin treatment. The study design is a nested case-cohort study. The investigators will recruit 600 patients and expect 200 individuals to have side effects and 400 without during a 24-month study period. Fecal samples will be collected at baseline, 2 months, and 4 months or when gastrointestinal symptoms occur. All fecal samples will be sequenced by 16s rRNA (ribosomal ribonucleic acid) sequencing to obtain a baseline microbiota profile; a subpopulation consisting of homogenous groups of participants will be in depth-analyzed using shotgun sequencing. If the hypothesis is confirmed this project may lead to bacterial therapies that will allow more patients tolerate metformin.
Interventions
DRUGMetformin
Receiving Metformin is no study intervention. The investigators have no influence on the Metformin treatment. All participants receive Metformin provided by the health care system. The individual case determine dose and frequency of the treatment as part of the usual therapy guidelines.
Sponsors
Göteborg University
Örebro University, Sweden
Linkoeping University
Karolinska Institutet
Umeå University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Type 2 diabetes (diagnosis set within the last 12 months) * planned metformin treatment * Age: 40 - 80 years * Have provided written informed consent.
Exclusion criteria
* already started treatment with Metformin * intestinal disease incl. irritable bowel syndrome * treatment with antibiotics in the last 3 months * Inflammatory disorder t.ex. rheumatoid arthritis * anemia, haemoglobinopathy * alcohol or drug abuse * cancer disease under treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| change from baseline in the fecal microbiota composition by detecting bacteria families with help of relative abundance (%) and diversity metrics | 4 months | Faeces samples will be collected at baseline, after 2 months and after 4 months of Metformin treatment and analysed using 16S rRNA sequencing, whole genome shotgun sequencing and metagenomic analyses |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| number of patients with gastrointestinal side effects | 4 months | A questionnaire will be answered at baseline, after 2 and 4 months and refers to a period of 2 weeks before study visit. Six different side effects will be monitored: loss of appetite, nausea, vomiting, diarrhea, meteorism, stomach ache. |
| rate of gastrointestinal side effects | 4 months | Changes in the rate of side effects using questionnaire at baseline, after 2 and 4 months.The answer possibilities are: never, one or a few times, daily, multiple times a day. |
| time to first appearance of gastrointestinal side effects | 4 months | How many months till the onset of side effects during metformin treatment: depending on the time of assessment, 2 or 4 months |
| genetic correlation between Microbiota and gastrointestinal side effects | 4 months | The microbiota genome and the relation to the appearance of gastrointestinal side effects will be analysed. |
| time to first appearance of side effects which requires termination of the Metformin treatment | 4 months | Analysing length of metformin treatment and relation to appearance of side effects |
| correlation between microbiota and beneficial glucose lowering response | 4 months | Plasma glucose will be analysed at baseline, after 2 and 4 months of Metformin treatment and correlated to the changes in the composition of microbiota. |
| time to first appearance of side effects which requires dose changes in the Metformin treatment | 4 months | Analysing changes in metformin treatment and relation to appearance of side effects |
Countries
Sweden
Contacts
Primary ContactOlov Rolandsson, Professor
Outcome results
None listed